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Abstract: Chronic subdural hematoma (CSDH) is common squeal of trauma and rarely 
associated with anticoagulant therapy, antiplatelet, chemotherapeutic drugs, arterio-
venous malformation, aneurysms and post-craniotomy. However its   occurrence is very 
unusual with systemic haematological malignancy and mostly reported with acute 
myeloid leukemia; however incidence of SDH occurrence in chronic myelogenous 
leukemia (CML) is very rare. CML is a haematological malignancy characterized by 
chromosomal alteration, pathologically represents increased proliferation of the 
granulocytic cell line without   loss of capacity to differentiate. CML has three phases – 
remission phase, accelerated phase and blast crisis. About 85 % of patients present in 
remission phase of disease and carries a favorable prognosis. As intracranial, subdural 
hematoma usually occur in the accelerated phase or blast crisis phase or extremely 
uncommon during chronic remission phase, although only those affected, who are 
neglecting therapeutic medication or discontinued therapy or rarely as an adverse effect 
of medications. However, important role of neurosurgeon lies in early detection and 
correction of platelet count and associated hematological abnormality as quite sizeable   
proportion of cases may not need surgical intervention instead can be managed 
conservatively under regular supervision in association with oncologist colleague, but 
few cases may need urgent surgical intervention. So, selecting a subgroup of CML cases 
in the remission phase requiring surgical intervention, presenting with CSDH is not only 
challenging, as failure to make an informed and timely precise  decision can lead to 
catastrophic worse outcome and even mortality. So, purpose of current article is to 
formulate the management therapeutic plan. Authors report three cases of CML   in 
chronic remission phase, receiving treatment under guidance of Haemto-oncologist at 
our institute presented with spontaneous chronic SDH. The  mean age was 36 years 
(range 29- 44 years), 66% were male, headache was presenting feature in all 100% (n=3), 
66% cases were hemiplegic and 33% unconscious each, in 66% cases CSDH were located 
on right fronto-temporal region and 33% had small left sided thin CSDH. About were 
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66% cases (n=2) were managed surgically by burr hole placement and drainage drain 
placement while 33% case (n=1), who had thin CSDH was managed conservatively. 
Favorable outcome was observed in   100% cases (n=3) Outcome was favorable in all of 
our cases.     
Key words: chronic myeloid leukemia, remission phase, chronic subdural hematoma, 
management 
 
Introduction 
Chronic subdural hematoma (CSDH) is an 
important cause of morbidity and usually 
caused by  previous trauma, post-craniotomy 
surgery, thrombocytopenia,  chronic 
alcoholism, radiation induced or intake of 
various medications  including anticoagulants, 
antiplatelets or following rupture of 
intracranial aneurysms (1-4, 5), arterio-
venous malformations (5) and cocaine drug 
abuser (8). It is very rarely reported to occur 
with intracranial neoplasms like meningioma 
(10), rhabdomyosarcoma (15).  Association of 
C SDH is reported with lymphoma (16), 
choriocarcinoma (18), however, its   
occurrence is very unusual with systemic 
haematological malignancy and mostly 
occurred in association with acute myeloid 
leukemia. CSDH occurrence is extremely 
uncommon in chronic myeloid leukemia 
(CML), but few cases are reported in form of 
isolated case –report, tend to occur only in the 
accelerated phase of CML Authors present   
three cases of chronic SDH occurrence in 
chronic remission phase of CML, who were 
treated at hemato-ontological clinic, were in 
the remission phase of CML, developed 
CSDH, managed successfully.   
Case illustration one 
A 35 year male reported with complains of 
with insidious onset gradually progressive 
headache, vomiting, left sided hemiparesis and 
altered sensorium for last two weeks with no 
antecedent history of trauma, alcohol or oral 
anticoagulants or antiplatelets intake. He was 
diagnosed as case of CML, about 18 weeks 
back. At present, he was in the chronic 
remission phase receiving maintenance dose 
of oral tyrosine kinase inhibitor imatinib 
mesylate.  On neurological examination at 
admission, he was drowsy with Glasgow Coma 
Score (GCS) of 13 with pupils’ bilaterally 
normal size and briskly reacting to light. Left 
sided seventh nerve upper motor neuron 
paresis and spastic hemiparesis along with 
brisk deep tendon jerks and plantar were 
bilaterally extensor. Haematological 
investigations were within normal limit with 
mild leucocytosios.  
CT scan head, revealed presence of  right 
sided fronto-parietal hypodense chronic SDH, 
volume were about 60 ml and  causing mass 
effect with 8 mm midline shift  to the left 
(Figure 1). A right frontal and parietal burr 
hole were made and hematoma evacuation 
was carried out under local anesthesia and 
intravenous sedation. Post-operative NCCT 
head subsidence of mass effect with no 
residual CSDH. He gradually improved 
clinically and was discharged in stable 
condition with GCS of 15.  
He was re-admitted with similar 
complaints of headache and right sided 
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weakness 6 months later. Hemogram and 
coagulation profile were within normal limits. 
Repeat NCCT head, showed mixed density 
fronto-parietal SDH on contra lateral left side   
(Figure 2).  Magnetic Resonance Imaging 
(MRI) was carried out to rule out brain 
parenchyma lesion which revealed presence of 
sub-acute subdural hematoma over left 
frontoparietal region (Figure 3). He 
underwent left sided frontal and parietal burr 
hole and hematoma evacuation with 
uneventful recovery. Histopathology report 
and cytopathological analysis of subdural fluid 
were inconclusive for any malignant 
infiltration of dura mater or subdural 
membrane or subdural fluid. He was doing 
well without any further recurrence; however, 
maintenance medication for CML was 
continued in consultation with haematology 
department. Patient was still in chronic phase 
at twelve months following first surgery. 
 
 
Figure 1 - Pre-operative non-contrast CT scan head 
showing right sided hypodense chronic SDH,  
extending over fronto-parietal region causing mass 
effect (Case 1) 
 
Figure 2 - Repeat non-contrast CT scan head at   six  
months following first surgical  burr hole drainage 
showing   fresh SDH development on contralateral 
side located  overleft fronto-parietal area (Case 1 ) 
 
 
Figure 3 - MRI brain, T2WI,axial section  at   six  
months follow-up to correlate CT findings, following 
 first surgical  evacuation of SDH  showing  no 
residual SDH ,but newly developed   SDH     on 
 contralateral side   located  overleft fronto-
parietal region  (Case 1 ). 
Case illustration two 
A 44 year male was referred to 
neurosurgical emergency services from 
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haematology department with   outpatient 
department with complains of persistent 
headache and progressive left hemiparesis for   
one month. No other relevant history or co 
morbid illness was elicited. He was diagnosed 
with CML about one year back and presently 
in chronic remission phase   on maintenance 
therapy. On neurological evaluation, his GCS 
was 15/15, with left sided upper motor neuron 
type facial nerve paresis. Power in left upper 
and lower limb was 4/5. Haematological 
parameters were within normal limits.  
CT scan head revealed presence of chronic 
SDH in right fronto-temporo-parietal region 
measuring approximately 45 ml with mass 
effect and midline shift of 5 mm. He 
underwent elective burr whole drainage of 
SDH. Intra-operative, altered blood with 
thickened pseudo-membrane surrounding it. 
Histopathogical evaluation of     dural 
membrane biopsy and cytopathology of 
subdural fluid was also non-contributory. 
Post-operative NCCT head showed near-
complete evacuation of SDH and relief of mass 
effect. He had uneventful postoperative phase 
with recovery of hemiparesis. He tolerated 
surgical procedure well. At the last follow- up 
6 months following surgery, he was doing well 
and continuing to receive maintenance 
therapy of tyrosine kinase inhibitor.   
Case illustration three 
 A 29 year old female reported our 
outpatient services with   gradually worsening 
headache for 3 weeks. She also had no other 
significant history except diagnosis of with 
CML, six months back and currently on in 
chronic phase on maintenance therapy under 
supervision of haematologist. Neurological 
examination was unremarkable and 
haematological investigations showed platelet 
count and coagulation profile within normal 
limit.  
NCCT head revealed hypodense left side 
thin fronto-temporal chronic SDH measuring 
about 15 ml. (Figure 4) the findings were 
confirmed on MRI (Figure 4). She responded 
well to conservative management without 
further increase in size. She was kept on 
regular follow- up on outpatient services basis 
for six months till her follow up CT scan 
revealed complete resolution of hematoma.  
 
 
Figure 4 - Non-contrast enhanced MRI brain T1WI, 
axial section hyperintense signal intensity  , SDH 
showing over left side fronto-temporal area (Case- 3) 
Discussion  
Chronic Myelogenous Leukemia (CML) is 
a haematological malignancy characterized by 
chromosomal alteration, typically showing 
reciprocal translocation between 
chromosomes 9 and 22, observed 
approximately in 90% cases. Pathologically   
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represents increased proliferation of the 
granulocytic cell line without   loss of capacity 
to differentiate.  
 The clinical course of CML can be   sub-
classified into three phases – chronic phase, 
accelerated phase and blast crisis.  About 85 % 
of patients of chronic remission phase   carry a 
favorable prognosis, if kept on long- term 
tyrosine kinase inhibitors maintenance 
therapy. However, chronic stage can also 
progress to either accelerated phase or blast 
crisis phase accompanying with unfavorable 
prognosis, if left untreated in 
chemotherapeutic resistant cases. 
Predominant factor for differentiating  among 
both   phases is presence of 10-19 % 
myeloblasts and greater than  20 % myeloblasts 
in peripheral blood  smear or bone marrow 
examination  in former and latter respectively 
(7, 20).  
However, with advent of newer selective 
tyrosine kinase inhibitors,     treatment of CML 
is revolutionized   with   improved outcome, 
80-90 % long- term survival rates. (12)   During 
course of therapy very few cases may develop 
major intracranial bleeding, who were 
receiving medication for CML treatment 
under combined supervision of haematologist 
and oncologist.  
Chronic subdural haematoma contains an 
inner and an outer capsule. The capillary 
endothelial cells lining of capsules contains 
cytoplasmic protrusions and fenestrations. 
Mean age in the present series was 36 years 
(range 29-44 years) compared to 50 years as 
mean age at presentation, with male to female 
ratio was 2:1 compared to 1.3: 1 as reported in 
Jonte et al series. (6) Patients in chronic phase 
of disease had favorable outcome with 100% 
survival rate during short term follow up. 
Authors   advocated   further evaluated of these 
cases should be carried to rule out   systemic 
haematological malignancy. (6)   
Spontaneous SDH occurrence in 
association with solid malignancy may have 
additional history of precipitating factors like 
head injury, however such history is usually 
absent in haematological malignancy 
specifically acute myeloid leukemia (14); 
although rare, an only very few cases have been 
reported in association with other systemic 
haematological malignancy (1, 2, 3, 9, 11, 17, 
19).  
Exact mechanism of SDH occurrence in  is 
still  debated,    various postulates  are put 
forward    including  – malignant cell deposits  
causing occlusion of dural blood vessels,  
rupture of occluded dural blood vessels into 
subdural space and tumor necrosis in 
metastatic deposits, thrombocytopenia 
secondary to chemotherapeutic agent therapy, 
development of disseminated intravascular 
coagulation disorder. Even direct secondary 
dural leukemic deposits are postulated to 
explain repeated recurring SDH following 
surgical intervention.  Our first case had right 
sided frontotemporal CSDH and after six 
months following evacuation, developed 
CSDH on contralateral side necessitating 
surgical intervention on that side also.  Cases 
with diagnosed case of CML, who are put 
chemotherapeutic treatment, may carry 
increased risk of intracranial haemorrhage 
depending on stage of primary disease. In a 
study conducted by Druker et al, observed 
incidence of intracranial haemorrhage in CML 
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patients, who are on    medical treatment in the 
range of – 5 % in blast crisis phases, 1 % in 
accelerated phase and almost negligible risk of    
0.6 % in the chronic remission phase. (4). the 
occurrence of chronic SDH in chronic phase 
of disease is extremely uncommon.  However, 
our cases were very unique as all were in 
chronic remission phase, who were on regular 
treatment    under care of haematologist 
supervision receiving tyrokinase inhibitor 
imatinib mesylate   or Dasatinib, according to 
optimal requirement in response to therapy.   
However, histopathological evaluation of 
biopsy specimen of dural membrane ruled out 
presence of any malignant cell deposit and 
further cytopathology of subdural fluid was 
negative for malignant cells in all our cases.  
However,   mechanism of intracranial 
bleed remains  elusive    despite presence of 
normal haematological parameters i.e., 
platelet count and coagulation profile,       
dysfunction of platelet aggregation and 
reduced α2-plasmin inhibitor factors and even 
acquired Van Will brand  disease was  are also 
incriminated. (9, 13)       Giuffrè suggested role 
hormonal factors, in addition to mechanical, 
hematogenic and vasogenic factors, could play 
an important role in the pathogenesis of these 
hematomas. (21)   
CSDH can either increase in volume size 
and clinically presents with focal neurological 
deficit and   mass effect or extremely rarely 
cam even show slowly resolution over time.  
Mechanism of gradual progression in size of   
the chronic subdural haematomas were 
attributable     to CSF passage caused due to 
osmolarity gradient, which in turn caused by   
blood degradation products.   However, 
recently   proposed mechanism attribute   to 
leaking capillaries causing repeated 
microhaemorrhgaes taking place into the 
haematoma cavity.   The leaking component 
may exceed the resorptive capacity of chronic 
subdural haematomas, leading to its 
enlargement all of our patients were   clinically 
and haematologically in remission phase with 
strict supervision and guidance of therapy 
under haematologist at our institute. All the 
patients had platelet counts and coagulation 
profile within normal range. (21) These may 
be cause of deterioration of our two cases, 
 Treatment of subdural hematoma is 
usually surgical evacuation in symptomatic 
cases, however, CSDH occurring secondary to 
coagulation disorder or hematological 
malignancy may even responds to correction 
of haematological abnormality and with relief 
of mass effect or resolution of ASDH even 
without any need of surgical intervention. As 
our two cases needed surgery and 33 % cases 
responded to conservative treatment.    
Surgical approach of CSDH management 
include   burr whole craniostomy with or 
without drain placement, mini craniotomy or 
rarely   craniotomy and excision of thick 
membrane in those cases   with extremely thick 
membrane or repeated failure of burr whole 
craniostomy.   In the current study, two out of 
three cases,   required surgical evacuation of 
SDH and  underwent burr whole evacuation 
by placing frontal and parietal burr holes and 
irrigation and drain was also kept for three 
days following surgical procedure. In the 
postoperative period scan revealed complete 
evacuation.  Fortunately   third case did not 
required surgical intervention. Our cases had 
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no complication except one case (case1),   who 
during follow-up   period,   developed new 
onset CSDH on contralateral side   at six 
month following initial surgery, which also 
required surgical   evacuation and all three 
cases are under regular follow-up on 
maintenance therapy under hemato- 
oncologist. Prognosis of CML associated with 
CSDH in remission phase is definitely better   
than the blast or crisis phase. In 2015 authors  
reported development of CSDH ma during 
accelerated  phase of Chronic Myeloid 
Leukemia presented with seizure, who had  
and rapid progression course and had fatal 
outcome despite  surgical intervention, 
however, CSDH was diagnosed after a delay, 
accordingly author further  recommends 
timely selection of potential surgical candidate 
as requirement of ASDH is critical in addition 
to timely surgery to provide  for good 
neurological outcome along with high degree 
of suspicion is must. (23) 
 
TABLE I 
Summary of chronic myeloid leukemia cases, who developed chronic subdural hematoma and 
management outcome 
Sl. 
No  
Age (Year) 
/Sex  
Clinical 
features 
NCCT Head  CML stage/ 
Chemo-
therapy 
Interval of 
SDH  
occurrence 
followings 
diagnosis of 
CML 
Hematologi
cal investi-
gation  
Managemen
t 
Follow-up   Remark  
1 35/M  Headache, 
unconscio-
usness 
Right fronto-
temporal    
Chronic 
remission    
/ yes 
4 months Within limit   Right sided 
burr hole, 
after    6 
months   
burr hole  
on left  side  
2 years  
doing well 
Fresh 
Chronic 
SDH on 
contralateral 
side 6 
month  
following 
the  first 
surgery  
2 44  /M Headache, 
Hemiparesis 
Right fronto-
parietal 
Chronic 
remission  / 
yes 
One year  Within limit Burr hole 
drainage 
18 months  
well 
 - 
3 29/ F  Headache Left thin 
frontotemporal 
region      
Chronic 
remission  / 
yes 
Six months Within limit Conservative  17 months 
doing well 
  - 
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Conclusion 
Chronic subdural hematoma can be 
associated with recent history of physical 
trauma, drug intake, coagulation disorder and 
very rarely haematological malignancy. 
Chronic myeloid leukemia can be 
predisposing factors especially during blast 
crisis phase.   All our cases were already 
diagnosed case on maintainace therapy for 
CML in the chronic remission phase presented 
with headache and focal neurological deficit. 
Two out of three were managed surgically and 
rest one responded favorably to medical 
therapy. It is especially important to select 
subgroup of patients among all cases, who are 
potential surgical candidate, otherwise delay in 
selection and treatment can produce 
catastrophic event.  It is prudent to be vigilant 
in all case of chronic CML and other 
hematological malignancy, especially those 
cases developing headache or focal 
neurological deficit and haematologist should 
also be warned about possibility and 
minimum CT scan head must be carried out at 
the first suspicion of any developing   
intracranial pathology   mass lesion without 
wasting golden time. 
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